Cargando…

Blood protein predictors of brain amyloid for enrichment in clinical trials?

BACKGROUND: Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood-based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large-scale prevention t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashton, Nicholas J., Kiddle, Steven J., Graf, John, Ward, Malcolm, Baird, Alison L., Hye, Abdul, Westwood, Sarah, Wong, Karyuan Vivian, Dobson, Richard J., Rabinovici, Gil D., Miller, Bruce L., Rosen, Howard J., Torres, Andrew, Zhang, Zhanpan, Thurfjell, Lennart, Covin, Antonia, Hehir, Cristina Tan, Baker, David, Bazenet, Chantal, Lovestone, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Blood-Based Biomarker
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876903/ https://www.ncbi.nlm.nih.gov/pubmed/27239491 http://dx.doi.org/10.1016/j.dadm.2014.11.005

Ejemplares similares

Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
por: Voyle, Nicola, et al.
Publicado: (2015)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline
por: Uchida, Kazuhiko, et al.
Publicado: (2015)

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker
por: Oh, Esther S., et al.
Publicado: (2015)

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
por: Bettcher, Brianne M., et al.
Publicado: (2016)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individuals
por: Shi, Liu, et al.
Publicado: (2021)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds
por: Fatima, Tahzeeb, et al.
Publicado: (2021)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Blood-based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts
por: Royall, Donald R., et al.
Publicado: (2019)

Plasma microRNA vary in association with the progression of Alzheimer's disease
por: Guévremont, Diane, et al.
Publicado: (2022)

Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease
por: Peloso, Gina M., et al.
Publicado: (2018)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Blood-based metabolic signatures in Alzheimer's disease
por: de Leeuw, Francisca A., et al.
Publicado: (2017)

Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain
por: Hwang, Kristy S., et al.
Publicado: (2015)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Repeated systemic inflammation was associated with cognitive deficits in older Britons
por: Tampubolon, Gindo
Publicado: (2015)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Thrombopoietin is associated with δ's intercept, and only in Non-Hispanic Whites
por: Royall, Donald R., et al.
Publicado: (2016)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study
por: Li, Danni, et al.
Publicado: (2016)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)
por: Li, Danni, et al.
Publicado: (2016)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment
por: Yamamoto-Imoto, Hitomi, et al.
Publicado: (2018)

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
por: Gupta, Veer Bala, et al.
Publicado: (2017)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f8nvg94tah58vhg1nbuaqod09e